1. Executive Summary
2. Research Methodology
3. DNA Vaccines
3.1 Vaccines
3.2 Overview
3.2.1 History of DNA Vaccine
3.2.2 Components of Plasmid DNA Vaccine
3.3 DNA Vaccine Mechanism
3.4 DNA Vaccine Delivery Methods
4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by End-User
4.2.2 Market Share by Clinical Trials
4.2.3 Market Share by Region
5. Regional Analysis
5.1 North America
5.1.1 Market Sizing (Actual & Forecasted)
5.2 Europe
5.2.1 Market Sizing (Actual & Forecasted)
5.3 Asia Pacific
5.3.1 Market Sizing (Actual & Forecasted)
6. Market Dynamics
6.1 Industry Trends & Developments
6.1.1 DNA Vaccine Clinical Pipeline
6.1.2 Mergers & Acquisitions
6.1.3 Investments in the Industry
6.2 Growth Drivers
6.2.1 Higher Incidences of Infectious Diseases
6.2.2 Increasing Adoption in Animal Healthcare
6.2.3 Growing Demand for Novel Vaccines
6.2.4 Advantages over Conventional Vaccines
6.3 Challenges
6.3.1 Ambiguous Regulatory System
6.3.2 Less Market Penetration
6.3.3 Incompatibility with Other Vaccines
7. Competitive Landscape
8. Company Profiles
8.1 Novartis International AG
8.2 Merck & Co., Inc.
8.3 GlaxoSmithKline plc.
8.4 Sanofi Pasteur SA
8.5 Pfizer Inc.